De Luca, K <br/><br/>
The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate.  [electronic resource] 

 -  Leukemia  Nov 2009 
 - 2063-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2009.155  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antigens, CD34--metabolism<br/>B-Lymphocytes--cytology<br/>Cell Differentiation--drug effects<br/>Cell Line<br/>Cell Lineage--drug effects<br/>DNA-Binding Proteins--genetics<br/>Fetal Blood--cytology<br/>Hematopoietic Stem Cells--cytology<br/>Humans<br/>Lipopeptides--pharmacology<br/>Lymphopoiesis--drug effects<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Myeloid Cells--cytology<br/>Stromal Cells--cytology<br/>Toll-Like Receptor 1--agonists<br/>Toll-Like Receptor 2--agonists<br/>Transcription, Genetic--drug effects